Overview

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Status:
Terminated
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).
Phase:
Phase 2
Details
Lead Sponsor:
Sublimity Therapeutics Holdco Limited
Collaborator:
Dr. Falk Pharma GmbH
Treatments:
Cyclosporine
Cyclosporins